Globus Medical, Inc. $GMED Shares Purchased by Annex Advisory Services LLC

Annex Advisory Services LLC raised its position in Globus Medical, Inc. (NYSE:GMED) by 6.4% in the second quarter, Holdings Channel reports. The fund owned 372,794 shares of the medical device company’s stock after buying an additional 22,407 shares during the period. Annex Advisory Services LLC’s holdings in Globus Medical were worth $29,454,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Elevation Wealth Partners LLC increased its position in shares of Globus Medical by 2,178.6% in the 2nd quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company’s stock valued at $25,000 after purchasing an additional 305 shares during the last quarter. Advisory Services Network LLC purchased a new stake in shares of Globus Medical during the 3rd quarter worth $26,000. EverSource Wealth Advisors LLC lifted its position in shares of Globus Medical by 74.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after purchasing an additional 197 shares during the last quarter. SBI Securities Co. Ltd. grew its stake in shares of Globus Medical by 98.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after purchasing an additional 167 shares in the last quarter. Finally, Parallel Advisors LLC grew its stake in shares of Globus Medical by 45.1% during the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after purchasing an additional 173 shares in the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

Insiders Place Their Bets

In related news, Director David D. Davidar sold 25,000 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the sale, the director owned 510,175 shares in the company, valued at $41,201,733. This represents a 4.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 18.38% of the stock is currently owned by corporate insiders.

Globus Medical Trading Down 1.2%

Shares of NYSE GMED opened at $85.13 on Wednesday. Globus Medical, Inc. has a twelve month low of $54.15 and a twelve month high of $101.40. The stock has a 50 day moving average of $79.59 and a two-hundred day moving average of $85.06. The stock has a market cap of $11.56 billion, a P/E ratio of 21.77, a P/E/G ratio of 1.39 and a beta of 0.95.

Globus Medical (NYSE:GMED) last announced its earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.24. The business had revenue of $789.61 million for the quarter, compared to analyst estimates of $782.88 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period last year, the firm posted $0.86 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, research analysts predict that Globus Medical, Inc. will post 4.99 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently commented on GMED. Stifel Nicolaus dropped their target price on Globus Medical from $95.00 to $80.00 and set a “hold” rating on the stock in a report on Wednesday, July 8th. Needham & Company LLC upped their price objective on Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. UBS Group started coverage on Globus Medical in a report on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 price objective on the stock. Wall Street Zen lowered Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a research note on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $101.77.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.